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INTRODUCTION 
Historically, the ultimate goals of cancer chemotherapy have been 
to depress the growth of neoplasms, alleviate suffering and prolong the 
life of the host. The ability of currently used cancer chemotherapeutic 
agents to achieve these goals is in part limited by their toxic manifesta­
tions. In addition to controlling the growth of neoplasms, these com­
pounds also act on any other rapidly proliferating tissues in the body 
such as hematopoietic tissues, lymphoid tissues, the epithelial lining 
of the gastrointestinal tract and reproductive cells. Thus the clinician 
must walk a thin line between death of his patient due to the tumor and 
death due to the toxic properties of the therapeutic agent. 
Assay systems for the anticancer properties of compounds have 
utilized laboratory animals with inducible neoplasms. Assays for the 
toxic manifestations of potential anticancer agents, to date, have been 
of secondary importance. Possibly if extensive assay systems for the 
toxic properties of potential cancer chemotherapeutic agents were also 
devised, then information from both types of assays could bring cancer 
chemotherapy closer to its ultimate goals. 
The philosophy guiding these investigations was: if an assay system 
for the other toxic properties of anticancer compounds can be devised 
which is sensitive enough, it could be used to detect minute differences 
in toxic activities of compounds due to slight molecular structural 
differences. Then it may be possible to engineer away from the undesir­
able toxic structures by the addition or subtraction of chemical radicals 
while retaining their desirable anticancer properties. 
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Studies were initiated to determine if the calf assay system could 
be further refined so as to be able to detect differences in toxic 
activities of closely related structural analogues. Attempts were made 
to equate graded dosage levels of alkylating agents with responses of 
the calf other than the time of occurrence of death. 
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LITERATURE REVIEW 
Biological Assay Responses of Animals 
The biological assay is a technique in which unknown substances 
and/or unknown amounts of substances are administered to animals (6). 
The responses of the animals are compared qualitatively and quantitatively 
to the responses of animals to known substances. 
The responses of animals which can be measured are numerous. Life 
or death of animals in response to compounds is one of the easier 
measurements made. Other responses which can be measured are changes in 
blood pressure and varying degrees of growth, increase and regression, 
of the animal body or a single organ (6). Many attempts have been made 
to determine if the animal's responses can be equated to graded dosage 
levels of an experimental substance. Such attempts have been successful 
only when the responses measured were dose related. 
Graded responses of animals to compounds ' 
Laboratory animals have long been used in numerous and varied 
procedures for determining graded responses of physiologically active 
compounds or agents. These investigations generally have been preceded 
by other investigations with the same compounds in which the presence or 
absence of a response had been noted. 
Young rats have been used as the biological assay animal for vitamin 
A determinations (30). The rats are allowed to become vitamin A depleted. 
They are then fed vitamin A-free diets to which graded amounts of the 
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unknown substance are added. The rate of growth of the rats is then 
compared to that of rats fed known amounts of vitamin A and the amount of 
vitamin A activity in the unknown substance is determined. 
Biological assay techniques are also prominent in endocrine research. 
Graded amounts of follicle stimulating hormone (FSH) administered to 
immature female rats have been sho\m to elicit a graded growth response 
in the ovary (53). One of the more sensitive biological assay techniques 
in endocrine research is the ovarian ascorbic acid depletion technique 
used for the detection of graded amounts of lutenizing hormone (LH) (10). 
The LH is injected into specially prepared immature female rats and the 
ovarian ascorbic acid is determined after four hours. 
There are also toxins which produce a graded response in laboratory 
animals. Aflatoxin is a toxin from certain strains of Aspergillus flavus 
which mimics actinomyocin D and inhibits DNA-dependent RNA synthesis (4). 
Newberne, e^  al. (33) have shown that graded amounts of this toxin 
produce a graded amount of bile duct proliferation and hepatocarcinoma 
formation in the livers of rats. 
Although the small laboratory animals are generally used for 
biological assays, the graded response is not limited to these laboratory 
species. Shupe, et al. (51) have shown that graded amounts of fluorine 
produce graded amounts of damage to the teeth of cattle. The adult bovine 
animal would probably not be used as the assay system for fluorine, but 
this illustrates that both large and small animals are capable of showing 
graded responses. 
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General responses of animals and man to hematopoietic tissue poisons 
The literature abounds with details of agents of industrial or 
therapeutic importance and of feeding stuffs which have been shown to be 
potent hematopoietic tissue poisons. Wintrobe (62) lists many varied 
agents which have this toxic property including benzene, antibiotics, 
ionizing radiation and anticancer agents. There are also feeding stuffs 
such as bracken fern (13,19) and trichloroethylene-extracted soybean oil 
meal (19,37) which in the past have caused a tremendous amount of economic 
damage to the cattle industry because of their hematopoietic tissue 
poisoning properties. 
Benzene is used as a solvent in many commercial industries (62). 
This agent causes a pancytopenia or a depletion of all of the cellular 
elements in the circulating blood. Benzene is an example of a known 
toxic compound which is still used in industry. Elaborate safety 
precautions have been devised to allow the continued use of this indus­
trially important compound. 
Chloramphenicol is a broad spectrum antibiotic which is widely used 
in the chemotherapy of microbial infections (62). This compound is a 
very potent hematopoietic tissue poison especially in certain humans 
where it also causes a pancytopenia. Although chloramphenicol can be a 
very toxic compound, its usefulness often outweighs its disadvantages. 
Experimental findings in dogs (42) and clinical findings (12) have 
suggested that the toxic manifestations due to this compound occur with 
chronic use, but do not appear to be dose related. There are no reports 
available in which attempts have been made to determine if graded 
responses occur with this agent. 
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Ionizing radiation has proven to be very toxic not only for hemato­
poietic tissue but also any other rapidly proliferating tissues of man 
and animals (2,7,26). This is an example of a laboratory and industrial 
poison which also has therapeutic usefulness. The dog, pig, burro (2) 
and calf (43) have been shown to be extremely sensitive to ionizing 
radiation. All animals have been sho:fn to give the characteristic 
"aplastic anemia" response of thrombocytopenia, leukopenia, hemorrhage 
and death to this agent. Schultze, et al. (48) have shown that the calf 
is the most sensitive animal to gamma radiation. 
Many species of animals; mice, rats, dogs and monkeys, in addition 
to man, are sensitive to the hematopoietic tissue poisoning properties 
of cancer chemotherapeutic agents (5,16,36,41,45,46,50). The time of 
occurrence of death of animals in response to cancer chemotherapeutic 
agents is the most quantitative response established to date and is the 
basis of toxicity assays for these compounds (45,46). The time of occur­
rence of signs of hematopoietic tissue poisoning has been at most a qual­
itative criterion in these toxicity assays, Sternberg, et al. (54) have 
reported that lymphoid depletion is one of the main microscopic changes 
in tissues due to the alkylating types of anticancer compounds. They 
reported an apparent increase in lymphoid depletion with an increase in 
dosage levels but no attempts were made to quantitate the graded lesions. 
Schmidt, et al. (45,46) did attempt to equate clinical and gross 
changes with graded dosage levels of mechlorethamine«HCl (HN2) given to 
dogs and monkeys. Their findings suggest that graded amounts of tissue 
damage occur with graded amounts of HN2. However, changes reported in 
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lymphoid tissues consisted of suggestions of gross decreases in size of 
the lymph nodes and the spleens of dogs and monkeys. 
Several reports suggest that the dog is the most sensitive assay 
animal for the toxic properties of anticancer compounds (16,41,45,46,64). 
Bailey (1) has presented evidence that the calf is 2-5 times more 
sensitive than the dog to HN2 and uracil mustard (UM). These findings 
suggest that the calf may be a better assay animal for certain alkylating 
types of cancer chemotherapeutic agents. 
A forage substance which will induce "aplastic anemia" in cattle is 
bracken feim, Pteridium acquilinum (13,14,15). This toxic plant affects 
both young and old cattle, but the condition occurs generally when there 
is little other forage present for the animals to eat. No attempts have 
been reported to determine if graded responses occur in cattle with this 
substance. 
A feed ingredient which was once of much concern to the cattle 
industry of Scotland, Germany and the United States is trichloroethylene-
extracted soybean oil meal (TCESOM) (37). This toxic meal can induce in 
cattle a classical response of hematopoietic tissue poisoning or "aplastic 
anemia" very similar to that produced by ionizing radiation in animals (48). 
This toxic entity has been shown to induce a graded response in cattle. 
Picken, et al. (38) and Pritchard, et al. (40) have shown that the young 
calf is a good biological assay animal for this toxic meal. 
Many investigators have shown that hematopoietic tissue poisons are 
capable of inducing a graded response in various species of animals. The 
quantitative response of the calf to TCESOM and the greater sensitivity 
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of the calf to ionizing radiation and certain cancer chemotherapeutic 
agents suggest that the calf may be a more sensitive assay animal for 
hematopoietic tissue poisons. 
Responses of calves to hematopoietic tissue noisons 
The young calf was first shown to be sensitive to hematopoietic 
tissue poisons when it was determined that bracken fern, Pteridium 
acouilinum. was the cause of an "aplastic anemia" in cattle while on 
forage especially during late summer (13,14,15). The toxic principle 
of bracken fern is unknown but has been shoim to be thermolabile (15). 
Although there have been a considerable number of investigations (13,14, 
15,19) dealing with bracken poisoning, there have been no reported 
attempts to quantitate the responses of calves to this toxic forage. 
Perman, et al. (35), Picken, et al. (38) and Pritchard, et al. (40) 
have shown that the young calf is a good, easily housed experimental 
animal for the assay of the toxic properties of TCESOM. They have shown 
that the calf is sensitive and quantitative in its response to graded 
dosage levels of TCESOM. The times of occurrence of the events of 
thrombocytopenia, leukopenia, relative lymphocytosis, visible hemorrhages, 
temperature spike and death have been quantitative in their response to 
graded dosage levels of this toxic meal. 
McKinney, et al. (27) synthesized two compounds, S-(dichlorovinyl)-
L-cysteine (DCVC) and S-(dichlorovinyl)-L-glutathione (DCVG), which were 
capable of inducing a syndrome in calves similar to that reported for 
TCESOM. Derr, et al. (8), McKinney, et al. (28,29), Perman, et al. (35) 
and Schultze, et al. (47), using DCVC in a variety of dosage regimens; 
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single dose, multiple dose, oral and intravenous, have shown that the 
young calf responds in a quantitative manner to graded dosage levels of 
DCVC. McKinney, et al. (27) also reported that DCVC was more toxic to 
the calf than its structural analogue, DCVG. Strafuss and Sautter (58) 
reported that gradations of lymphoid depletion and bone marrow hypoplasia 
were produced by DCVC but no quantitation was attempted. 
The quantitative response of the young calf to TCESOM and DCVC and 
the report of Schultze, e^  al. (48) showing that the calf was more 
sensitive than other animals to the hematopoietic tissue poisoning 
properties of ionizing radiation, suggested to Bailey (1) that the calf 
might be a good assay animal for other hematopoietic tissue poisons. His 
studies involved investigating the responses of the calf to the toxic 
properties of several cancer chemotherapeutic agents. Bailey (1) gave to 
calves graded daily dosage levels of mechlorethamine.HCl (HN2), uracil 
mustard (UM), 5-fluorouracil (5-FU) and amethopterin (AMETH). His 
findings showed that the time of occurrence of death of the calves 
treated with graded dosage levels of the two alkylating agents, HN2 and 
UM, was quantitative. His results also suggested that the calf was 2-5 
times more sensitive to these comnounds than the reportedly sensitive 
dog and 5-10 times more sensitive than the rat. Other findings included 
data showing that UM on a molar basis was 2 times more toxic to the calf 
than its analogue, HN2. Bailey (1) reported that the calf was sensitive 
but not quantitative in its response to 5-FU and not at all sensitive to 
AMETH. 
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Bailey's (1) studies suggest that the calf may be a more sensitive 
assay animal for the toxic properties of certain closely related alkylating 
agents. If the calf is sensitive enough, then it might be used to exploit 
the possibility of using more highly developed assays to aid in the 
development of new and better cancer chemotherapeutic agents. 
Expression of Dose-Response Relationships 
Drug dosages in human and animal medicine have been used to define 
the quantity of a therapeutic compound required to produce a given 
response (55). The size of the animal as indicated by its weight has 
been a useful criterion by which to govern the dosage levels. The 
problem has been in the transposition of dosage levels between species 
of animals because the smaller species require more compound per unit of 
body weight to produce a desired effect than do the larger species (55). 
Recently, Freireich, e^  al. (17) and Pinkel (39) have shown that the 
use of body surface area has been a useful criterion for the adjustment 
of drug dosages between different species for cancer chemotherapy. The 
body surface area is a variable which can be expressed as a function of 
weight (17). Even though investigators are continually searching for 
other means by which to establish drug dosages, body weight appears to be 
the most reliable criterion for adjusting dosage levels. 
The amount of a physiologically active agent or compound per unit 
of body weight required to induce a measurable response in an experimental 
animal is an expression of a dose-response relationship (6,5b). Several 
complex mathematical manipulations have been devised to more adequately 
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define the dose-response relationship. One technique is to compare the 
intensity of a response expressed as a percentage with the dosage level 
which has undergone a logarithmic transformation (55). Other methods 
have used Lineweaver-Burk plots in attempts to further define the dose-
response relationships (21). 
Regardless of the means of expressing dose-response relationships, 
none of the presently used methods, elaborate though they may be, of 
expressing dose-response relationships gives an adequate definition of 
the therapeutic effectiveness or the damage to the tissues of interest 
produced by an administered compound. Blood levels of therapeutic 
compounds have been widely used to give an indication of the therapeutic 
effectiveness of compounds (22,57,61). In some instances, dosage levels 
per unit of body weight of presently used therapeutic agents have been 
established to maintain certain blood levels. This is the case with 
penicillin in that dosage levels which produce and maintain barely 
detectible blood levels appear to be sufficient for therapeutic effective­
ness (22). In the field of cancer chemotherapy. Tan and Cole (59) have 
recently suggested that blood levels of anticancer agents may be used as 
indicators of therapeutic effectiveness. 
Simon (52) and Weinstein (61) theorize that blood levels of compounds 
should indicate to some extent the concentration of the compounds in the 
tissue fluids bathing each individual cell. Since many therapeutic 
compounds are present in the blood in complexes with proteins in addition 
to the free forms (3,55), Bonneycastle (3) suggests that plasma or blood 
levels have little meaning. Bonneycastle (3) and Stowe (57) suggest that 
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the blood concentration of a compound is only a rough estimate of the 
amount of drug remaining in the body regardless of form. 
To date, none of the methods of expressing dose-response relation­
ships involves an adequate definition of the actual damage produced in 
the tissues due to an administered compound. Blood or plasma levels of 
therapeutic compounds, even though there is disagreement about their 
validity or usefulness, are still the only means by which attempts can 
be made to adequately establish the amount of a compound or substance 
which elicits a certain observable response such as tissue damage. 
Mechloretharaine-HCl (2,2'-dichloro-N-methyl-diethylamine) (HN2) and 
uracil mustard (5-[bis(2-chloroethyl)amino]-uracil) (UM) are alkylating 
agents which have widespread use in cancer chemotherapy (34). The 
structures of these compounds are as follows: 
These two compounds are structural analogues and differ only in the car­
rier portions of the molecule, the methyl group on the HN2 and the uracil 
moiety on the UM (23). These compounds are polyfunctional alkylating 
agents in that they are capable of inducing the phenomena of alkylation 
Mechlorethamine-HCl and Uracil Mustard 
/CHf-CHz-Cl 
CH2-CÏÏ2-CI 
H 
Mechlorethamine•HCl Uracil Mustard 
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two or more times before becoming inactive (23,24). Both of these com­
pounds have a crystalline structure. HN2 is extremely soluble in water 
but UM is insoluble. Schumacher and O'Connell (49) have used the adju­
vant, dimethylacetamide (DMA.), to increase the solubility of UM in water. 
Bailey (1) did not observe toxicity differences in calves treated with 
UM due to the presence of small quantities of DMA.. The DMA. did appear 
to enhance the solubility of the UM in water (1). 
Mode of action 
Alkylation can occur in any electron rich center in the body, but 
most alkylating agents of therapeutic value appear to have a prediliction 
for several sites (24). The main site of action is thought to be at the 
7' position of guanylic acid. The ensuing reactions are thought to be 
cleavage of the bond with the sugar moiety and disruption of the DNA 
chain. Johnson and Bergel (23) suggest that other possible sites of 
action are the cleavage of the imidazole ring of purines and the causing 
of interactions between two separate DNA chains, between DNA and certain 
proteins and also between two separate proteins. 
Shanbrora, al. (50) have postulated that UM is capable of acting 
as an antimetabolite due to its uracil moiety but there is no evidence to 
substantiate this thesis. Their thesis could be a possible explanation 
for Bailey's (1) findings that UM was two times as toxic to the calf as 
HN2. However, Johnson and Bergel (23) present evidence that different 
carrier portions of the alkylating agent molecule vary the efficiency of 
the alkylation reaction. This may indicate that the uracil moiety 
induces more efficient alkylation than the methyl moiety. 
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Determination of Alkylating Agents in Tissue Fluids 
The extensive use of alkylating agents in cancer chemotherapy has 
demanded the development of sensitive assay techniques for these agents 
in tissue fluids. Several methods for the detection of alkylating agents 
have been developed. 
labeled mechlorethamine.HCl (HN2) has been used as a method for 
determining the tissue levels and distribution of this compound (32). 
Nadkami, e^  al. (32) have shovm that over 90 percent of the activity 
leaves the blood within 30 seconds in mice. Mellett and Woods (31) 
suggest that a limitation of this method is that the labeled carbon stays 
with the break-do:fn products and does not give an adequate indication of 
the unchanged parent compound remaining in the tissues. 
Mellett and Woods (31) have reported a fluorometric technique for 
determining alkylating agents in tissue fluids. This technique is reported 
to be specific for the unchanged parent compound and appears to be the 
most sensitive technique reported in the literature. Blood and plasma 
concentrations detected with this procedure have been as low as 0.02 /ig, 
of HN2 per ml. of blood or plasma. The authors (31) have shown that 90 
percent of the HN2 activity disappears from the blood of dogs within 4 
minutes in contrast to the 30 seconds reported in mice using labeled 
compounds (32). The fluorometric technique of Mellett and Woods (31) is 
a multistage procedure and requires a large volume of plasma, 5 ml., for 
each determination. Tan and Cole (59) suggest that because of its com­
plexity and large volume of plasma required, the fluorometric technique 
is not designed for routine clinical procedures. Mellett and Woods (31) 
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report that time is an important factor in their procedure, but they 
do not define the limitations. 
Friedman and Soger (IS), Tan and Cole (59) and Klatt, et al. (25) 
have reported the use of gamma-(4-nitroûenzyl)pyridine (NBP) for deter­
mining the presence of alkylating agents in tissue fluids. This reagent 
is a nucleophilic agent which when combined with an alkylating agent 
under alkaline conditions produces a blue color (18). The amount of color 
has been shown to have a linear relationship with increasing concentrations 
of HN2 between 1 and 10/ig. per ml. of plasma (18). 
Epstein, e^  al. (11) first described the use of NBP in a method for 
the quantitative estimation of alkylating agents in an aqueous solution. 
Friedman and Soger (18) described a technique for detecting alkylating 
agents in tissue fluids using NBP. Their method involved deproteinization 
with IN hydrochloric acid followed by development of the color in an 
aqueous solution. The colored pigment was extracted with an equal volume 
of ethyl acetate and determined in a colorimeter. They found that the 
color formed was stable only for 3-5 minutes. The sensitivity of this 
procedure was reported to be 1/ig. of HN2 per ml. of tissue fluids. 
Tan and Cole (59) described a procedure with NBP for detecting 
alkylating agents in a small volume of plasma. This method involved 
deproteinization with zinc sulfate and barium hydroxide. The color 
pigment was formed in the protein-free filtrate and the colored compound 
was concentrated and extracted in a small volume of ethyl acetate.' The 
solution was centrifuged, the ethyl acetate upper layer placed in a micro-
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cuvette and the optical density of the solution was determined. The 
color was reported to be stable for 3-5 minutes. The sensitivity of the 
technique was reported to be 0.05 jag. of HN2 per ml. of plasma. 
Klatt, e^  al. (25) also have reported a procedure utilizing NBP in 
determining alkylating agents in plasma. This technique involves depro-
teinization and interaction with the NBP in the same step. The color is 
read in an aqueous solution. The color is reported also to be stable for 
only 3-5 minutes. In contrast to the method of Tan and Cole (59), there 
are no centrifugation and extraction manipulations between color formation 
and determining the optical density of the colored solution. The sensi­
tivity of this technique is reported to be 0.05 pmoles of HN2 per ml. of 
plasma or about O.ljjg. per ml. of plasma. 
The techniques reported in the literature for determining alkylating 
agents are multistep, complicated procedures. The fluorometric procedure 
appears to be the most sensitive technique, but it is also the most 
complicated. The procedures utilizing NBP as the color reagent are less 
sensitive than the fluorometric technique by factors of 1/5 to 1/2 and 
are less complicated. Time appears to be an important factor in both the 
fluorometric and NBP techniques for determining alkylating'agents. 
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TiATERIALS AND METHODS 
Experimental Animals 
Calves of mixed breeds and sexes were purchased from several local 
sources. These calves weighed from 37 to 74 kg. The animals were housed, 
two per stall, in clean, well ventilated concrete stalls. In good weather, 
the animals had access to a large fenced outside area. 
The rations consisted of a commercial powdered milk preparation^  
with grain, grass hay and fresh water available at all times. 
After receipt, the calves were conditioned for a period of one to two 
weeks. This conditioning period was essential to establish the state of 
health of the calves. This period was also used to measure the physio­
logical parameters to be determined during the experimental period in 
order to establish the base line values for each individual animal. 
During the experimental period, clinical examinations were made daily 
on each calf to detect signs which could be attributable to the test 
compounds. The calves were weighed weekly to establish the growth 
responses and to allow adjustment of the dosage levels. 
The hair on the necks of the calves was kept closely clipped over 
the jugular veins to allow adequate disinfection of the areas. Blood 
samples were collected and the test compounds were administered via the 
jugular veins. The test compounds were given on the basis of a prede­
termined amount per unit of body weight. 
D^ari Dri; Milk Specialties, Inc., Dundee, Illinois. 
One ml. blood samples were collected with siliconized^  needles and 
syringes for thrombocyte counts. Ten ml. of blood were collected in 
evacuated containers^  with the dipotassium salt of ethylenediaminetetra-
acetic acid (K2EDTA) as the anticoagulant for the remaining hematologic 
procedures and for determining plasma levels of alkylating agents. Five 
additional ml. of blood were collected in evacuated containers^  with no 
anticoagulant. Serum was harvested from this blood sample and frozen for 
future serum protein evaluations. 
Test Compounds 
The cancer chemotherapeutic agents used in this investigation were 
obtained from a local retail source. 
Mechlorethamine » HCl 
The mechlorethamine«HCl^  was furnished in sterile, 10 mg. vials. 
This compound was reconstituted daily with 10 ml. of sterile water to 
make a final concentration of 1 mg. per ml. 
Uracil mustard 
The uracil mustard^  was supplied in one mg. capsules. The contents 
of the capsules were emptied into sterile volumetric flasks of sufficient 
S^iliclad; Clay-Adams, Inc., New York, N. Y. 
2 Vacutainer; Becton, Dickinson and Co., Rutherford, N. Y. 
O 
Mustargen hydrochloride; Merck, Sharp and Dohme, Division of Merck 
and Co., West Point, Pa. 
U^racil mustard; The Upjohn Co., Kalamazoo, Mich. 
19 
size. Sterile saline (0.85% NaCl) was added to make a final concentration 
of 1 mg. per ml. Solutions of uracil mustard with a concentration of 1 rag. 
per ml. were also prepared with diraethylacetaraide as the solvent. All 
solutions were prepared daily and the excesses were discarded. 
Peripheral Blood Evaluations 
The physiological parameters measured in the peripheral blood were 
total thrombocyte count, total erythrocyte count, total leukocyte count, 
differential leukocyte count, packed cell volume and hemoglobin 
determination. 
Thrombocyte counts 
Thrombocyte counts were made with a disposable dilution system^  
described by Gerarde (20). The dilutions were made at the time of 
obtaining the blood sample. A drop of blood from a siliconized syringe 
was placed on a paraffin block to facilitate the use of the disposable 
dilution system. The diluted blood was used to charge a hemocytometer 
and the counts were made with the use of a microscope. 
Erythrocyte and leukocyte counts 
Erythrocytes and leukocytes were enumerated using a disposable 
dilution system^  and an electronic particle counter^  as described by 
U^nopette No. 5805; Becton, Dickinson and Co., Rutherford, N. J. 
U^nopette No. 5865; Becton, Dickinson and Co., Rutherford, N. J. 
3 Coulter Counter Model F; Coulter Electronics, Inc., Hialeah, Fla. 
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Gerarde (20). The particle counter was calibrated for calf blood cells 
using methods reported by Weide, et al. (60) and Wisecup and Crouch (63). 
Differential leukocyte counts 
Blood smears were made and stained by the Wright's method as described 
by Schalm (44). The stain was applied for a three minute period. A 
similar quantity of the buffer solution was mixed with the stain and 
allowed to remain on the slide for an additional five minute period. The 
slide was washed with tap water, air dried and examined by the oil 
immersion technique. One hundred cells were differentiated for each 
differential count. 
Packed cell volume 
The packed cell volume was determined by the microhematocrit method 
(44). A microhematocrit^  centrifuge and reader were used in this procedure. 
Hemoglobin determinations 
The cyanmethemoglobin method for hemoglobin determination was used 
(9,44). The disposable dilution system^  described by Gerarde (20) was 
utilized. The developed color was read in a spectrophotometer^  at 540 vyi. 
C^lay-Adams, Inc., New York, N. Y. 
9 * U^nopette No. 5857; Becton, Dickinson and Co., Rutherford, N. J, 
S^pectronic 20; Bausch and Lomb, Inc., Rochester, N. Y. 
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Scrum Protein Evaluations 
Total serum proteins 
The total serum proteins were determined by the Biuret method using 
a commercially prepared reagent^ . Duplicates were run on each serum 
sample. Six ml. of the Biuret reagent were added to 0.1 ml. of serum, 
mixed and placed in a water bath at 37® C for 30 minutes. The optical 
density was determined at 540 with a spectrophotometer^ . Standard 
curves were prepared using a commercial protein standard^ . 
Electrophoresis of serum proteins 
The serum protein fractions were evaluated with a cellulose acetate 
electrophoresis system^ . A buffer system of pH 8.6 and ionic strength 
of 0.05 was utilized in this procedure. The cellulose acetate strips 
with serum applied were placed in the electrophoresis chamber for 90 
minutes with an amperage of 1.5 ma. per strip. The strips were stained 
with Ponceau S and cleared with a solution of 13 percent acetic acid in 
absolute methanol. The strips were scanned with a densitometer^ . The 
densitometer readings were plotted on graph paper and the area under the 
curve for each peak was determined by planimetric techniques. The 
albumin-globulin ratios were determined from these values. 
H^ycel, Inc., Houston, Texas. 
n 
Spectronic 20; Bausch and Lomb, Inc., Rochester, N. Y. 
O 
Dade Reagents, Miami, Fla. 
G^elman Instrument Co., Ann Arbor, Mich. 
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Determination of Plasma Levels of Alkylating Agents 
Reagents 
1. ZnSO^  (reagent grade), 6 percent (w/v) in water. 
2. Ba(0H)2 (reagent grade), 65 gm. per liter of boiled water, filtered 
and stored under soda lime. 
The ZnSO^  and Ba(0H)2 solutions were titrated against each other to 
a phenolphthalein end point of pH 8.2. The titration was confirmed with 
a pH meter^ , 
3. Acetate buffer, glacial acetic acid was diluted and neutralized with 
IN NaOH to pH 4.6. The concentration of the acetate ion was adjusted 
to IN. 
4. Gamma-(4-nitrobenzyl)pyridine, 5 percent (w/v) in fractionally 
distilled methyl-ethyl ketone (boiling point range of 78-80° C). 
5. Triethylamine (reagent grade), 50 percent (v/v) in acetone. 
6. Methyl acohol (reagent grade). 
7. Plasma for the subsequent preparation of standard curves was harvested 
from adult bovine blood and frozen in 40 ml. aliquots. 
Preparation of alkylating agent standard curves 
Ten mg. of mechlorethamine-KCl (HN2) was diluted to 100 ml. with 
deionized water making a final concentration of 100 ug. per ml. Standard 
solutions were prepared by the addition of a sufficient amount of the 
M^odel GS; Beckman Instruments, Inc., Fullerton, Calif. 
23 
diluted HN2 to the stock bovine plasma. Concentrations used were 0.5, 
1.0 and 2.0of HN2 per ml. of plasma. A standard curve was prepared 
for each assay. 
Method for determination of HN2 in calf nlasma 
A predetermined amount of alkylating agent was administered to a 
calf via the jugular vein. Blood samples were taken at zero time and at 
intervals of 1, 2, 5, 10 and 20 minutes following the administration of 
the compound with the previously described evacuated 10 ml. tubes with 
K2EDTA, mixed and placed in an ice bath. The blood samples were centri­
fuged and two 2 ml. aliquots were taken from each plasma sample. To each 
2 ml. sample of plasma, 2.3 ml. of the ZnSO^  solution, an equivalent 
amount of the Ba(0H)2 solution and 0.4 ml. of methyl alcohol were added. 
The solutions were thoroughly mixed^  following the addition of each 
reagent. The mixtures were centrifuged and 4.0 ml. of the clear super­
natant s were placed into clean test tubes and placed in an ice bath. 
0.2 ml. of the acetate buffer and 0.4 ml. of the NBP reagent were added 
to each of the cooled tubes. The solutions were thoroughly mixed and 
glass marbles were placed on top of the tubes. The samples were digested 
at 80-90° C for twenty minutes and then cooled in an ice bath. The 
cooled mixtures were centrifuged and 3.0 ml. of the supematants were 
placed into previously calibrated spectrophotometer^  tubes. Two ml. of the 
triethylamine (TEA) reagent were added to each sample and the solutions 
V^ortex Jr. Mixer; Scientific Industries, Inc., Springfield, Mass. 
S^pectronic 20; Bausch and Lomb, Inc., Rochester, N. Y. 
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were mixed by inversion. Optical density readings were made starting five 
minutes after the addition of the TEA reagent to the first tube with a 
spectrophotometer^  set at 565 ryi. All readings were completed within 
45 minutes following the digestion period. All samples and standards were 
assayed in duplicate. 
Necropsy Techniques 
Necropsies were performed on all experimental animals. Animals not 
dying due to the experimental procedures were electrocuted. All observed 
gross lesions were noted and recorded for subsequent evaluation. Tissues 
with gross lesions and representative lymphoid tissues, spleen, thymus 
and the right popliteal lymph node, were placed in buffered 10 percent 
formalin for preservation. All preserved tissues were processed for 
staining with hematoxylin-eosin and examined microscopically. 
S^pectronic 20; Bausch and Lomb, Inc., Rochester, N. Y. 
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EXPERIMENTAL 
The purpose of the investigation was to determine the nature of the 
relationships between graded dosage levels of two administered alkylating 
agents, tnechlorethamine»HCl (HN2) and uracil mustard (UM), and the 
responses produced in the calf. Major emphasis was to be placed on the 
tissue responses. A secondary phase of the investigation was to determine 
if plasma levels of the alkylating agents, HN2 and UM, administered to the 
calf could be detected and characterized. Attempts would be made to 
relate the plasma levels to the dosage levels and the tissue responses 
observed. 
Determination and Characterization of Plasma Levels of Alkylating Agents 
Selection and refinement of the method 
Characterization of plasma levels of compounds can be accomplished 
by defining the magnitude of the peak levels, duration of the levels or 
possibly defining the areas under the plasma level curves. Many blood 
samples are required to adequately characterize a plasma level of a com­
pound. This requirement placed an immediate limitation on the technique 
for alkylating agent determination to be employed. 
The fluorometric technique of Mellett and Woods (31), the most 
sensitive technique for alkylating agent determination reported in the 
literature, was obviously the method of choice based on its reported 
sensitivity. It was also the most complex technique reported for the 
determination of alkylating agents in plasma. This complexity was not 
desirable because of the number of samples required for the proposed studies. 
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The less complex Rroup of techniques for determining alkylating 
agents in plasma all employed gamraa-(4-nitrobenzyl)pyridine (NBP) as the 
color reagent. These techniques were reported to be less sensitive than 
the fluorometric method. A decision was made to examine all of the NBP 
procedures and try to determine which procedure readily lended itself 
to the particular needs of the proposed studies. A review indicated that 
all of the techniques utilizing NBP as the color reagent followed a 
similar pattern; a deproteinization step, a step involving reaction of 
the alkylating agent with the NBP reagent at elevated temperatures, 
development of the color under alkaline conditions and determination of 
the color produced by comparison with a standard curve. All authors 
(17,24,59) suggest that the color should be developed and read within 
45 minutes following digestion. 
The most sensitive method utilizing NBP reported, that of Tan and 
Cole (59.), was selected for the initial studies. This method involved 
the use of a plasma filtrate. The deproteinization step was by-passed 
for the initial studies and an aqueous solution of HN2 was prepared to 
simulate the plasma filtrate. An appropriate number of samples and 
blanks were used. The procedure of Tan and Cole (59) was followed except 
that all amounts were doubled. The NBP, 5 percent in acetone, plus the 
pH 4.5 acetate buffer were added and the solutions were heated in boiling 
water for 20 minutes. The solutions were cooled and acetone, ethyl acetate 
and sodium hydroxide (NaOH) were added. The samples were shaken and 
centrifuged. 
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A blue color could be seen in the ethyl acetate upper layer imme­
diately after the addition of the NaOH but the bulk of the color appeared 
to dissipate before the steps of centrifugation and transfer to the 
microcuvettes could be accomplished. The ethyl acetate upper layers were 
removed with Pasteur pipettes and placed in microcuvettes. All optical 
density (0. D.) readings obtained were comparable to the blank 0. D. 
readings indicating complete loss of the color in the initial experiment. 
Three additional trials were undertaken. Efforts were made to lower 
the manipulation times by using a smaller number of samples but there 
were no real improvements. The results indicated that the pigment was 
not stable for the 3-5 minute period as the authors (59) had suggested. 
The preliminary findings suggested that this procedure would not be 
desirable for the projected experiments. 
The method of Klatt, et al. (25) was the next NBP procedure examined. 
This procedure was reported to be one half as sensitive as the method of 
Tan and Cole (59). In this procedure, NBP reagent, water and acetic acid 
were added to the plasma and the mixture was heated at 80-90® C for 15 
minutes. The solutions were cooled and centrifuged. An aliquot of the 
supernatant was drawn off and added to an equal volume of triethylamine, 
50 percent in acetone, for color develonment. There were no centrifuga­
tion and extraction steps after the color development. 
Following the literature examination of the method of Klatt, et al. 
(25), it was decided to attempt to modify the method of Tan and Cole (59) 
by developing and reading the color in an aqueous solution as described 
by Klatt, et al. (25) in order to avoid the time consuming extraction 
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procedures. Acetone was retained as the NBP solvent as indicated by Tan 
and Cole (59), but triethylamine (TEA), 50 percent in acetone was used 
as the alkalifying reagent as suggested by Klatt, et al. (25). 
Simulated plasma filtrates were prepared by using aqueous solutions 
of HN2 with concentrations of 0.5, 1.0 and 2.0per ml. Two ml. of 
each concentration were used in triplicate and appropriate blank solutions 
were prepared. Appropriate volumes of acetate buffer and NBP reagent 
were added and the samples were placed in a water bath at 80-90° C for 
20 minutes. The tubes were cooled in an ice bath, the TEA reagent added 
and the color was determined. Despite several problems, a suprisingly 
straight line relationship was observed using this modified technique. 
The problems were bumping of the solutions during digestion with 
physical loss of contents, precipitate formation after digestion which 
hampered accurate pipetting, and high blank readings. An additional 
observation made was that the blue color had an initial surge of deep 
color and then it appeared to stabilize for a period of time. 
It was suggested that the high temperatures of digestion caused the 
evaporation of the NBP solvent and this was the reason for the bumping 
and precipitate formation. A change in the procedure was made to use 
methyl-ethyl ketone (MEK) (boiling point of 79.6° C) as the NBP solvent 
as suggested by Klatt, et al. (25). Bumping and precioitate formation 
were decreased to some extent but there were no appreciable improvements 
in the high blank readings. The surge of color persisted. The use of 
MEK with a boiling point of 79.6° C which was near the water bath 
temperature of 80-90° C appeared to decrease the problems. 
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It was thought that some low boiling fractions in the MEK may have 
been the cause of the bumping and high blank readings. A second exper­
iment was run in which fractionally distilled MEK (boiling point range 
of 78-80° C) was used as the NRP solvent. The blank readings were 
lowered by 0.01 0. D. units (0.06 to 0.05) but some bumping and precipi­
tate formation still occurred. 
Klatt, e^  al. (25) had reported the use of short-stemmed funnels in 
the mouths of the test tubes during digestion. Another experiment was 
designed in which the fractionally distilled MEK was used as the NBP 
solvent and a marble was placed on top of each tube during digestion. 
It was found that the bumping stopped and the precipitate formation was 
essentially alleviated. 
Further attempts were made to alleviate the occasional precipitate 
formation. An experiment was designed using fractionally distilled 
diethyl ketone (DEK) with a boiling point range of 101-103° C as the NBP 
solvent. The DEK was observed to be relatively insoluble in the aqueous 
solution. The addition of the TEA reagent caused the formation of a 
turbid solution instead of a clear, colored solution. No standard curves 
were obtained following this experiment. 
The results of the preliminary experiments with aqueous solutions of 
HN2 indicated that the modified Tan and Cole (59) method for alkylating 
agents gave a satisfactory straight line relationship between the 
concentration of the HN2 and the color produced. The use of fractionally 
distilled MEK as the NBP solvent and the TEA reagent as the alkalifving 
reagent appeared to give the best results. The blank readings obtained 
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with this procedure were high. These 0. D. readings were 0.05, but were 
very consistent from run to run. 
Preparation of standard curves for HN2 in bovine plasma 
The use of calves in following plasma levels of alkylating agents 
had not been previously reported. Attempts were made to prepare working 
standard curves for HN2 by adding known amounts of HN2 to bovine plasma. 
The Tan and Cole (59) method for alkylating agent determination in 
plasma called for deproteinization of the plasma with zinc hydroxide. 
Equal volumes of bovine plasma and 5 percent zinc sulfate (ZnSO^ ), an 
equivalent amount of a saturated barium hydroxide [Ba(0H)2Î solution 
and a small volume of methyl alcohol (MeOH) were mixed and processed as 
described by Tan and Cole (59). A clear plasma filtrate could not be 
obtained using these reagents. The equivalency of the ZnSO^  and Ba(0H)2 
solutions was rechecked, following titration to a phenolphthalein end 
point of pH 8.2, with a pH meter. Several attempts at deproteinization 
of the bovine plasma with the rechecked solutions were unsuccessful and 
clear filtrates were not obtained. 
A 6 percent solution of ZnSO^  was prepared and titrated against the 
saturated Ba(0H)2 solution. Clear plasma filtrates were still not 
obtained consistently. A further adjustment of the suggested volumes was 
undertaken. The use of 2.3 ml. of the 6 percent ZnSO^  solution, an 
equivalent amount of the Ba(0H)2 solution and 0.4 ml. of the MeOH were 
found to five satisfactory plasma filtrates with 2.0 ml. of bovine plasma. 
In addition, it was found that the solutions must be added to the bovine 
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plasma in the order mentioned and that the solutions must be thoroughly 
mixed following addition of each reagent before clear plasma filtrates 
could be routinely obtained. 
Several standard curves were prepared using concentrations of HN2 
as low as O.l^ g. per ml. of plasma to as high as lO.Oyug. per ml. of 
plasma. The curves obtained were satisfactory straight line curves, but 
there was some day-to-day variation. 
The amount of change of 0. D. units due to 0.1yug. of HN2 per ml. of 
plasma was only 0.003 0. D. units. This change in 0. D. units was easily 
within the normal fluctuation of the spectrophotometer^  being used. This 
suggests that errors ranging from 20 to 100 percent could be obtained 
with HN2 concentrations below 0.5jx%. per ml. of plasma. 
If the majority of the detected plasma levels in the proposed animal 
studies were found to be above 0.5yig. of HN2 per ml. of plasma, the error, 
even though large, could be acceptable. However, if the majority of the 
detected plasma levels were less than 0.5yig. of RK2 per ml. of plasma, 
the magnitude of the errors could render any interpretation of the results 
invalid. 
Decay of the color pigment 
The labile nature of the color pigment was still of concern even 
though the preliminary results indicated that it had not caused trouble. 
An experiment was designed to determine the decay curves for the color 
pigments from plasma filtrates. A single concentration of HN2, 1 ug. per 
S^pectronic 20; Bausch and Lomb, Inc., Rochester, N. Y. 
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ml. of bovine plasma, was used in these experiments. The experiments 
involved determining the 0. D. at 0.5, 1, 2, 5, 10 and 20 minutes fol­
lowing the addition of the TEA reagent while keeping within the 45 minute 
time limit. The results of three trials are presented in Table 1. 
Table 1. Change in 0. D. readings following the addition of TEA reagent 
Experiment 0.5 min. 1 min. 2 min. 5 min. 10 min. 20 min. 
1 0.020 0.019 0.019 0.015 0.014 0.014 
2 0.021 0.020 0.017 0.017 0.012 0.015 
3 0.023 0.019 0.016 0.018 0.011 0.011 
Average 0.021 0.019 0.017 0.016 0.012 0.013 
The results indicated that there was a steady loss of color over the 
first 10 minutes. Since there was no apparent early plateau after 
adding the TEA reagent, there was no appropriate time to make the 0. D. 
readings. A decision was made to make all 0. D. readings starting 5 
minutes after the addition of the TEA to the first sample. Following 
initiation of this procedure, it was found that all tubes could be read 
within 5-6 minutes after the addition of the TEA reagent. 
Decay of HN2 activity 
The use of animals and multiple sampling techniques in the proposed 
experiments indicated that there would be a time lapse between drawing 
the blood samples and determining the plasma levels of HN2. It was not 
known if this time interval was critical. An experiment was designed to 
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determine the decay of HN2 activity in both plasma and water. A concen­
tration of 1yig. of HN2 per ml. of plasma and water was used. The solutions 
were prepared to allow the HN2 to be in solution in either the plasma or 
water for 0, 60 or 120 minutes. The 0 time solutions were the last to 
be prepared and as soon as the dilutions were completed, all samples were 
taken through the previously described procedure of deproteinization, 
digestion with the NB? reagent, color formation and determination of the 
0. D. Triplicate samples were run for each time interval. Duplicate 
determinations were made for each HN2 solvent, plasma and water. The 
results of this experiment are presented in Table 2. 
Table 2. Average 0. D. readings for decay of 1yig. of HN2 per ml. of 
plasma or water 
Solvent 0 min. 60 min. 120 min. 
Plasma 0.018 ± 0.003 0.018 ± 0.003 0.020 ± 0.002 
Water 0.020 ± 0.002 0.020 - 0.002 0.018 ± 0.002 
These experiments indicate that there was no apparent loss of HN2 
activity in either plasma or water over a two hour period. To assure 
minimum loss of HN2 activity, it was decided to keep all blood samples 
in an ice bath until the samples were centrifuged, the plasma harvested 
and the plasma levels of HN2 were determined. 
Acceptable standard curves were obtained from plasma containing 
various concentrations of HN2. These curves were established with the 
use of plasma filtrates and following the final technique which is listed 
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in the materials and methods. There was some slight day-to-day variation 
in the curves but the slopes were constant. It was decided to prepare 
standard curves for each determination. The concentrations of HN2 to be 
used in the preparation of the standard curves were 0.5, 1.0 and 2.0yug. 
per ml. of stock plasma. 
Uracil mustard standard curves 
Klatt, et al. (25) have previously shown that their NBP procedure 
for alkylating agents could be used to detect uracil mustard in addition 
to HN2 in plasma. Attempts to prepare standard curves for uracil mustard 
(UM) using the procedure developed for HN2 were undertaken. 
A single trial was undertaken using both water and plasma as solvents 
for the UM. UM concentrations of 0.5, 1.0 and 2.0yig. per ml. of plasma 
or water were prepared. Uracil mustard could not be detected at any of 
the concentrations used. Two additional trials were made after recheck-
ing all reagents. Again, no alkylating agent activity could be detected 
in the UM standard solutions. No answer was readily apparent for this 
lack of success since Klatt, e^  al. (25) had reported the detection of 
UM with their technique. 
A decision was made not to pursue further any attempt to prepare a 
UM standard curve since plasma levels of alkylating agents were an area 
of secondary importance. UM would still be utilized in the main studies 
and attempts to monitor plasma levels of alkylating agents would be done 
only with HN2. 
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Validity of the assav method 
The results of all experiments to date indicated that acceptable 
standard curves for the alkylating agent, HN2, in plasma could be prepared 
using the modified technique. This modified technique appeared to give 
consistent results for plasma concentrations of HN2 above 0.5yig. per ml. 
The validity of this modified technique for determining plasma levels 
of HN2 below 0.5jag. per ml. appeared to be questionable. A decision was 
made to go ahead and monitor the plasma levels of HN2 in the graded 
dosage-tissue response animal studies with the modified technique. No 
data appeared to exist relating graded dosages of HN2 to the plasma 
levels obtained. Data obtained from the proposed monitoring could give 
worthwhile insight into the nature of the relationships. 
Preliminary animal experiments for determining HN2 plasma levels 
The animal experiments described in this section were designed to 
answer three questions. 
1. Can plasma levels of HN2 be detected in the calf following intra­
venous administration? 
2. Can graded plasma levels of HN2 be detected in calves given graded 
dosage levels? 
3. If graded plasma levels of HN2 are detected, can they be related to 
the responses of the calves to HN2? 
Preliminary experiments were undertaken to determine what dosage 
levels of HN2 were required to produce detectible plasma levels .of HN2 
in calves. These experiments were designed to determine when the peak 
levels of HN2 occurred and what were the durations of the plasma levels. 
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Using the same calf to eliminate as much individual variation as 
possible, two different dosage levels of HN2, 0.114 and 0.343jjmoles per 
kg. were administered. Each dosage level was given on a separate day and 
the animal was allowed 2 days rest between administrations. Blood samples 
were obtained at 0 time and 1, 2, 5, 10 and 20 minutes following the 
administration of the HN2. The blood samples were kept in an ice bath 
until centrifuged. Plasma was harvested from these blood samples and 
plasma levels of IIN2 were determined. The results of these experiments 
are presented in Table 3. 
Table 3. Duration of plasma levels of HN2 (^ g./ml.) following 
administration to the same calf 
Dosage Level 
jPmoles/kg. 
0 min. 1 min. 2 min. 5 min. 10 min. 20 min. 
0.114 0.00 0.00 0.00 0.00 0.00 0.00 
0.343 0.00 0.68 0.38 0.31 0.15 0.20 
These results show that all of the plasma levels were within the 
questionable range of the assay method except for the 1 minute sample with 
the higher dosage level. The findings suggested that a dosage level of 
0.114^ moles of HN2 per kg. was insufficient to produce a detectible plasma 
level with this method and 0.343^ moles of HN2 per kg. was sufficient. 
A second experiment was undertaken to establish the plasma levels 
produced by a much higher dosage level of HN2. The dosage level selected 
was chosen because it approximated dosage levels which had been reported 
37 
to produce detectible tissue damage in the dog (45). The dosage level 
chosen was 2.288yumoles of HN2 per kg. 
The same calf was used in this experiment that had been used in the 
previous experiments after a 7 day period of rest. The compound was 
administered on 2 separate days, two days apart. The plasma levels were 
monitored over a two hour period following each injection of HN2, The 
results of this experiment appear in Table 4. 
Table 4. Duration of nlasma levels of HN2 ^ g./ml.) following 
administration of 2.288yumoles per kg. to the same calf 
Time (minutes) 
Iniec- 0 1 2 5 10 20 30 60 120 
tion 
1 0.00 0.10 0.35 0.00 0.32 0.10 0.40 0.40 0.55 
2 0.00 0.50 0.50 0.20 0.28 0.28 0.28 0.12 0.00 
These findings show that all of the plasma levels detected appear 
to be in the questionable range of the standard curve. The maximum peak 
levels with both injections were comparable in magnitude but differed in 
the time of appearance. It is not known whether the variability was 
real or a reflection of the inadequacy of the analytical method. 
The plasma levels of HN2 detected in the preliminary experiments all 
approached or were well within the questionable area of the standard curve. 
However, a decision was made to continue to monitor the HN2 plasma levels 
in all of the proposed HN2 dosage-response studies to see if any relation­
ships or trends might be suggested. 
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Single dose studies with nN2 
The experiment involved two calves which were part of the HN2 dosage-
response studies. This experiment entailed administering single injections 
of HN2 to calves. The dosage levels selected were 2.288 and 4.576jumoles 
per kg. One level was administered to each calf. The plasma levels were 
monitored for 120 minutes. The results of this experiment are presented 
in Table 5. 
Table 5. Duration of plasma levels of HN2 [pg./ml.) following 
administration of two dosage levels 
Dosage Time (minutes) 
Level 
jjimoles/ 0 1 2 5 10 20 30 60 120 
kg. 
2.288 0.00 0.40 0.30 0.30 0.35 0.14 0.22 0.00 0.00 
4.576 0.00 0.00 0.15 0.55 0.55 0.55 0.00 0.00 0.00 
Inspection of these data show that while the higher dosage level 
produced the higher plasma levels, all plasma levels were still in the 
questionable range. Additional evaluation of the plasma level data 
showed that the areas under the curves for both plasma levels were 
approximately the same. It also can be noted that the 2.288jpmole dosage 
level in this experiment produced a similar plasma level to that observed 
from injection 2 in Table 4. 
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Multiple graded dosage levels of HN2 
An experimental plan of giving each animal 4 injections of HN2 at 
the same dosage level, one week apart, was designed. The plasma levels 
were monitored for twenty minutes with blood samples being obtained at 0 
time and 1, 2, 5, 10 and 20 minutes following the administration of the 
HN2. Four dosage levels of HN2 were selected; 0.286, 0.572, 1.144 and 
2.288yimoles per kg. per week. The results of the initial injection of 
each dosage level are presented in Table 6. 
Table 6. Duration of plasma levels of HN2 ^ g./ml.) following the 
initial injections of 4 different dosage levels 
Dosage Level 0 min. 1 min. 2 min. 5 min. 10 min. 20 min. 
0.286 0.00 0.30 0.00 0.00 0.30 0.00 
0.572 0.00 0.45 0.45 0.23 0.28 0.28 
1.144 0.00 0.10 0.00 0.00 0.00 0.00 
2.288 0.00 0.00 0.03 0.08 0.00 0.00 
All plasma levels detected following the initial injections of the 
HN2 were less than 0,5^ g. per ml. of plasma. The plasma level persisted 
for 20 minutes only with the dosage level of 0.572yimoles per kg. Plasma 
levels were detected for all dosage levels following the initial adminis­
tration. There were no apparent relationships between the dosage levels 
and the detected plasma levels since the lower dosage levels produced 
the higher plasma levels. 
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The findings from the initial administrations of HN2 did not hold 
with the remaining injections of HN2. Table 7 illustrates a summary of 
the plasma levels detected following each administration of each dosage 
level of HN2 in the multiple dose experiment. 
Table 7. Occurrence of detectible plasma levels of HN2 following 
4 administrations of different dosage levels, one week apart 
Dosage Level 
jumoles/kg. 1 
Injection Number 
2 3 4 
0.286 + — — — 
0.572 + — — — 
1.144 + + - + 
2.288 + + + + 
No detectible plasma levels were obtained following the remaining 
three injections of the two lower dosage levels of HN2 or the third 
injection of the 1.144jpmole dosage level. The reason for the failure 
to detect these subsequent plasma levels is not known. It can be theorized 
at least with the two lower dosage levels that the HN2 sensitized the 
calf's system in some manner which enabled it to clear the plasma much 
more rapidly than following the initial injections. 
Figures 1 and 2 indicate the actual plasma levels detected in the 
calves receiving the two higher dosage levels of HN2 over the 4 week 
period. The areas under the curves are also presented on these graphic 
presentations. The detected plasma levels produced by these two dosage 
levels give the appearance of being graded and dose related. 
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42 
2.288/1 MOLES HNa/KG./WEEK 
0.4-
|ST TREATMENT 
0.2-
2.9 cm 
0.4-
2ND t rea tment  0.3-
0.2-
5.1 cm 0.1-
< 0.4-
CO 
< 
_j 
ÛL 
3RD t rea tment  0.3-
• 0.2-
6.6 cm CO 
Z 
3: 
0.4-
4TH treatment 0.3-
0.2-
7.6 cm 
10 20 
TIME (MINUTES) 
"Figure 2, Duration of HN2 plasma levels in the calf 
43 
It is readily apparent from all of the experiments in which attempts 
were made to monitor the plasma levels of HN2 that there was a remarkable 
lack of consistency in the results. The plasma levels with the 1.144 and 
2.288^ mole dosage levels gave indications of being graded, but overall, 
including the preliminary experiments with HN2, the lower dosage levels 
appeared to produce higher plasma levels. 
It is of interest to note that there was one real consistency, the 
apparent ceiling of the peak plasma levels detected regardless of the 
dosage levels administered. This peak level, approximately 0.5-0.7 yig. 
per ml. of plasma, may be real because the analytical procedure had been 
shown to be able to detect levels up to twenty times this level in stock 
plasma. Preliminary experiments indicated that HN2 did not associate or 
adhere to the zinc hydroxide precipitant. The data presented in Table 2 
indicate that the HN2 did not appear to associate with other plasma 
constituents or the plasma protein-zinc hydroxide precipitate. These 
findings suggest that if more HN2 had been present in the original blood" 
than the level of 0.5-0.7jpg. per ml. detected in the plasma filtrate, it 
could have stayed ifith the erythrocytes following the harvesting of the 
plasma. 
Responses of Calves to Graded Dosage Levels of Alkylating Agents 
The major phase of the investigation was to observe the biological 
responses of calves to the alkylating agents, mechlorethamine*HCl (HN2) 
and uracil mustard (UM). Bailey (1) has previously reported that the 
time of occurrence of death of calves in response to graded daily dosage 
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levels of these compounds was quantitative. He also presented data that 
suggest that the calf is more sensitive to these compounds than other 
laboratory animals. 
The present studies were undertaken to determine if changes in other 
measurable parameters: hematologic, serum proteins and tissues, could 
be found to be related to graded dosage levels of these compounds. In 
order to determine the presence or absence of detectible graded responses, 
a definite protocol was established. Graded dosage levels of the compounds 
were to be administered to calves for a predetermined experimental period 
following which the animals would be killed and necropsied. 
It was decided to administer the graded dosage levels at 1, 7, 14 and 
21 days. The animals would be killed on day 28 and the tissues would be 
examined. Four dosage levels of each compound would be chosen and there 
would be one calf for each dosage level. A preconditioning period would 
be utilized to establish the base-line parameters and to allow each 
animal to serve as its own control. 
The physiological parameters measured two ti^ es a week in the calves 
during the preconditioning period and the experimental period were as 
follows: weight, temperature, total thrombocyte count, total erythrocyte 
count, total leukocyte count, differential leukocyte count, packed cell 
volume, hemoglobin, total serum proteins and albumin-globulin ratio. 
Temperature, erythrocyte, packed cell volume and hemoglobin data are not 
presented or discussed because no significant variations were observed 
in any of the experimental animals. 
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Preliminary experiments with mechlorethamine'HCl 
The protocol calling for 4 weekly injections of HN2 indicated that 
preliminary nrobes must be undertaken to determine a range of possible 
dosage levels for this compound in calves. The preliminary studies were 
undertaken to establish dosage levels of 1-ÎN2 which would produce detect-
ible responses in calves following a single injection. 
The dosage levels of HN2 chosen for the preliminary studies were 
2.288 and 4.576 jumoles per kg. These dosage levels were approximately 
the dosage levels which had been reported to produce tissue damage in 
dogs (45). Each dosage level was given to a separate calf and the 
responses of the calves were observed. The responses and results from 
this experiment are presented in Table 8. 
The data show that calf # 3, which received 2.288yimoles per kg., 
gained weight. Calf # 2, which received 4.576^ moles per kg., did not 
live long enough to show much weight change. 
Thrombocytopenia was not observed in the calves. It was of interest 
to note that the thrombocyte counts of calf # 3 dropped from 9.9 X 10^  per 
to 6.5 X 10^  per mm.^  two days following the administration of the 
HN2 and did not regain the magnitude of the original count until day 20. 
Leukopenia was observed in both calves. Calf # 3 developed a relative 
lymphocytosis up to 88 percent on day 7 and this was during a lymphopenic 
stage. The calf recovered from the leukopenia and the leukocyte counts 
remained within the normal range for the remainder of the experiment. 
The serum proteins were monitored only in the calf receiving 2.288 
m^oles of HN2 per kg. There was a fluctuation in the total protein levels 
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Table 8. Responses of calves to single doses of mechlorethamine'HCl 
Calf No. 2a 
Dosage Data 
Amt./kg./wk. 
(pmoles) 
Total Compound Given (mg.) 
m^oles) 
Number of Treatments 
Weight Data 
Initial (kg.) 
Maximum 
Final 
Thrombocyte counts 
Maximum (X 105/mm.3) 
Minimum 
Leukocyte Counts 
Maximum (/mm. ) 
Minimum 
Serum Proteins 
Maximum (gm. %) 
Minimum 
Diarrhea 
Death 
Gross Lesions 
Lymphoid Depletion 
440 880 
2.288 4.576 
33.0 50.8 
171.6 264.2 
1 1 
Gain Stable 
74.9 57.7 
84.4 (27) 57.7 
84.4 57.7 
9.9 (-2,20) 4.5 (4) 
6.5 (2) 
8,500 (13) 1,150 (4) 
2,150 (2) 
Stable 
4.9 (2) 
4.1 (7) 
Yes (5-6) Yes (2) 
Killed (35) Died (5) 
No Yes^  
Yes Yes 
O^nly one blood sample was obtained 
Indicates day of occurrence of event. 
L^esions not thought to be due to the compound. 
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and in the albumin-globulin ratios during the experimental period. No 
significance was attached to these fluctuations. 
Diarrhea occurred in both calves. It was only transitory in calf 
if 3 but was very severe in calf # 2. The nature of the diarrhea of calf 
# 2 was very fetid, greenish-white in color and had very little solid 
matter present. 
Death occurred in 5 days in the calf receiving 4.576 yimoles of HN2 
per kg. Death could be attributed to an ionic imbalance due to the 
severe diarrhea and possibly due to an overwhelming secondary bacterial 
infection. 
The calf which received 2.288^ moles of HN2 per kg. was clinically 
healthy 35 days post treatment. The calf was killed by electrocution. 
~ _ Gross lesions were observed only in calf # 2. These lesions were 
petechial hemorrhages on the epicardium and a few wide-spread patches of 
pneumonia in the lungs. The etiology of these lesions was thought to be 
due to a secondary bacterial infection resulting from the leukopenia and 
not primarily due to the HN2. 
Lymphoid depletion was the major microscopic finding in both animals. 
The magnitude of the lymphoid depletion was much greater in the calf which 
received 4.576^ moles of HN2 per kg. The calf which received 2.288jpmoles 
of HN2 per kg. showed small amounts of lymphoid depletion and may have 
been•recovering from the effects of the HN2 
It was apparent from these findings that the dosage level of HN2 of 
4.576^ moles per kg. was too high to be of any practical value for deter­
mining graded responses with the exception of the time of occurrence of 
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death. The apparent recovery of the calf receiving 2.288^ moles of HN2 
per kg. suggested that this dosage level could be satisfactory for the 
maximum dosage level in the graded dose-response studies. 
Multiple dose studies with mechlorethamine»HCl 
The dosage levels selected for these experiments were 0.286, 0,572, 
1.144 and 2.288yimoles of HN2 per kg. per week. The results of the 
graded multiple dose studies are presented in Table 9. 
The weight data in Table 9 show that only calf # 8 which received 
the highest dosage level had a marked weight loss. Calf # 4 which 
received 0.572 ^moles of HN2 gained a small amount of weight and the 
weights of calves if 5 and # 7 remained somewhat stable but did decrease 
in the latter days of the experimental period. The results indicated 
that the HN2 was having an effect upon the growth of the calves. 
The thrombocyte counts did decrease in all calves but the counts did 
not approach thrombocytopenic levels at any time. These findings are in 
contrast to the reported responses of calves to graded daily dosage levels 
of HN2 with which thrombocytopenic levels did occur (1). 
The leukocyte counts gave the first suggestions of a marked response 
of the calves to HN2. The degree of leukopenia which was observed appeared 
to be graded with increases in dosage levels. The calves receiving the 
two highest dosage levels had relative lymphocyte counts above 85 percent. 
The serum proteins fluctuated during the experiment and slight 
decreases were noted. The albumin-globulin ratios also fluctuated during 
the experimental period. There were no indications of graded responses 
of the serum proteins. 
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Table 9. Responses of calves to graded multiple doses of 
mechlorethamine.HCl 
Calf No. 5 4 7 8 
Dosage Data 
Amt./kg./wk. (pg.) 
(pmoles) 
Total Cpd. Given (mg.) 
(pmoles) 
No. of Treatments 
55 
0.286 
9.925 
51.61 
4 
110 
0.572 
28.55 
148.46 
4 
220 
1.144 
44.6 
231.92 
4 
440 
2.288 
66.4 
345.28 
4 
Weight Data 
Initial (kg.) 
Stable 
43.6 
Gain 
61.7 
- Stable 
48.12 
Loss 
39.5 
Maximum 45.4 (6) 69.9 (27) 52.66 (7) 39.5 (1) 
Final 44.9 69.9 49.9 35.4 
Thrombocyte Counts 
Maximum (X lO^ /mm.^ ) 9.3 (6) 8.3 (8) 10.0 (1) 9.45 (8) 
minimum 6.3 (16) 5.0 (28) 5.1 (18) 6.8 (22) 
Leukocyte Counts 
Maximum (/mm.3) 
Minimum 
Serum Proteins 
Maximum (gm. %) 
Minimum 
Diarrhea 
Death 
Gross Lesions 
Lymphoid Depletion 
10,450 (2) 9,800 (1) 6,250 (-3) 6,850 (-3) 
4,750(23) 3,650 (15) 1,900 (25) 1,300 (22) 
Decrease Decrease Decrease Decrease 
5.4 (2) 5.0 (1) 4.8 (1) 6.2 (2) 
4.5 (23) 4.1 (17) 4.0 (15) 4.5 (22) 
No No No Yes (10) 
Killed(28) Killed (28) Killed (28) Died (27) 
No No No Yes^  
Yes Yes Yes Yes 
(^ Indicates day of occurrence of event. 
L^esions not thought to be due to the compound. 
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Diarrhea occurred only in calf // 8 which received the highest dosage 
level and it persisted until the death of the calf. This severe diarrhea 
could have produced an ionic imbalance. 
The calf receiving 2.288yimoles of HN2 per kg. per week was the only 
animal that died during the experimental period and the other calves were 
electrocuted. It is suggested that a severe ionic imbalance in addition 
to a secondary bacterial infection could have contributed to the cause 
of death. 
At necropsy, gross lesions were observed only in the lungs of the 
calf receiving the highest dosage level. The pneumonia-like lesions 
were restricted to the anteroventral portions of the lungs. The lungs 
in these areas were dark red in color and had a firm consistency. 
Subsequent microscopic examination of the lesions showed that they were 
typical of a pneumonia. The alveoli in these areas were engorged with 
erythrocytes and had numerous septal cells, neutrophils and lymphocytes 
present. 
Lymphoid depletion was a prominent finding in the thymus, spleen 
and lymph nodes of all four animals. There were indications of graded 
amounts of lymphoid depletion corresponding to the graded increases of 
the dosage levels. Detailed evaluation of these lymphoid tissues will 
be discussed in a later section. 
The results of this graded multiple dose experiment with HN2 
suggest that there were graded dose-responses in these calves treated 
with HN2. The responses observed in the leukocyte counts and especially 
in the lymphoid tissues were highly suggestive of a graded response to HN2. 
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Preliminary experiments with uracil mustard 
A preliminary experiment was undertaken to establish a range of 
dosage levels for uracil mustard (U>0. It had been previously shown that 
UM, on a molar basis, was approximately two times as toxic as HN2 to the 
calf (1). A dosage level for UM of 2.288jumoles per kg. was selected. 
This level was equal to the highest dosage level in the multiple dose 
HN2 experiment and was one half of the highest HN2 dosage level used in 
the preliminary single dose HN2 experiments. 
Dimethylacetamide (DMA) had been used in intravenous injections of 
UM to increase the solubility of the UM (1). An internal experiment was 
added to determine if the DMA could be used in the remaining experiments 
with UM. One calf was given the UM with sterile physiological saline 
(PSS) as the UM solvent and another calf was given the same dosage level 
of UM with DMA as the solvent. It was observed that both solutions were 
essentially suspensions and the DMA did not enhance the solubility of 
the UM. The results of this preliminary experiment are presented in 
Table 10. 
Deaths occurred within 5 days in both calves and there was no real 
possibility for much weight change. The thrombocyte counts in both 
calves were similar and did not decrease to thrombocytopenic levels. 
There was a wide variation in the leukocyte counts in these two 
calves. The calf which received UM with PSS as solvent developed a marked 
leukopenia following administration of the compound. The calf which 
received UM with DMA as the solvent developed a marked leukocytosis 
which was in direct contrast to the other calf. It appeared that the DMA 
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Table 10. Responses of calves to single doses of uracil mustard 
Calf No. 10 11* 
Dosage Data 
Amt./kg./wk. (pg.) 
(pmoles) 
Total Compound Given (mg.) 
m^oles) 
Number of Treatments 
575 
2.288 
25.1 
99.0 
1 
575 
2.288 
27.7 
110.2 
1 
Weight Data 
Initial (kg.) 
Stable 
43.6 
Stable 
48.1 
Maximum 43.6 48.1 
Final 43.6 48.1 
Thrombocyte Counts 
Maximum (X 10^ /mm.^ ) 7.7 (-5) 8.9 (-6) 
Minimum 5.0 (1) 5.9 (4) 
Leukocyte Counts 
Maximum (/mm.^ ) 6,200 (-8) 25,200 (4) 
Minimum 1,700 (1) 7,150 (-9) 
Serum Proteins 
Maximum (gm. %) 
Stable 
6.3 (1) 
Stable 
4.7 (-9) 
Minimum 4.6 (-5) 4.5 (0) 
Diarrhea Yes (1) Yes (1) 
Death Died (4) Died (5) 
Gross Lesions Yesb Yesb 
Lymphoid Depletion Yes Yes 
D^imethylacetamide was used as the solvent for the UM. 
Indicates the day of occurrence of the event. 
L^esions not thought to be due to the compound. 
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could be the cause of the leukocytosis but this response of calves to DMA 
has not been reported. No explanation can be offered for this response. 
The serum proteins did not show any apparent changes. Both the 
total proteins and the albumin-globulin ratios fluctuated wildly and did 
not show any definite trends. 
Diarrhea occurred in both calves starting the day of administration 
of the UM. The diarrhea continued until the end of the experiment. 
Death occurred in both calves in 4-5 days. The times of death were 
comparable to the time of occurrence of death with HN2 at 4.576^ moles 
per kg. in the calf. This finding substantiates the reported finding 
that UM is approximately two times as toxic as HN2 to the calf. — 
The gross lesions which were observed in these two calves were 
similar to those observed in the calf which received 4.576jimoles of HN2 
per kg. These lesions were petechiation on the epicardium and patches 
of pneumonia in the lungs. These lesions were attributed to a possible 
secondary bacterial infection or a "toxemia" due to unknown causes. The 
UM was not thought to be the primary cause of the lesions. 
The major microscopic lesions observed in these two calves were 
lymphoid depletion in the thymus, spleen and lymph nodes. There were no 
apparent differences in the magnitude of the lymphoid depletion in either 
calf. The amount of lymphoid depletion in these two calves appeared to 
be similar to that observed in the calf which received 4.576jpmoles of 
HN2 per kg., again suggesting a factor of 2 difference in the toxicity 
of UM over HN2, A detailed discussion and evaluation of these micro­
scopic findings will be discussed in a later section. 
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The findings of this preliminary experiment with UM indicated that 
a dosage level of 2.288yimoles per kg. was much too high for the proposed 
graded dosage level studies in calves. The time of occurrence of death 
and preliminary information from observing the magnitude of the lymphoid 
depletion suggested that UM was two times as toxic as HN2 to the calf. 
Multiple dose studies with uracil mustard 
The dosage levels chosen for the multiple dose studies with UM in 
calves were 0.143, 0.286, 0.572 and 1.144^ moles per kg. per week. These 
dosage levels corresponded to one half the molarity of the dosage levels 
used in the multiple dosage studies with HN2. PSS was used as the UM 
solvent. The results of the multiple dose studies with UM appear in 
Table 11. 
The only animal that gained weight was calf # 17 which received the 
lowest dosage level of UM. The calves receiving the two intermediate 
dosage levels of UM lost weight and calf # 16 which received the highest 
dosage level of UM had a stable weight throughout the 28 day period. 
These findings indicated that the compound was having an effect on the 
growth of the animals. 
The thrombocyte counts of the calves receiving the two higher dosage 
levels of UM became low in the latter periods of the experiment and were 
at thrombocytopenic levels. The other two calves had decreases in the 
thrombocyte counts but the counts did not reach thrombocytopenic porpor-
tions. These findings are in contrast to the results of the HN2 experi­
ments and could indicate that UM is more thrombocytopenic in its action 
than HN2. 
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Table 11. Responses of calves to graded multiple doses of uracil mustard 
Calf No. 17 19 15 16 
Dosage Data 
Amt./kg./wk. (pg.) 
(jamoles) 
Total Cpd. Given (mg.) 
(pmoles) 
No. of Treatments 
36 
0.143 
6.6 
26.26 
4 
72 
0.286 
17.1 
67.86 
4 
144 
0.572 
24.7 
98.54 
4 
288 
1.144 
54.9 
218. 8 
4 
Weight Data 
Initial (kg.) 
Gain 
44.5 
Loss 
60.4 
Loss 
44.0 
Stable 
47.7 
Maximum 52.2 (27) 60.8 (13) 45.9 (20) 49.0 (6) 
Final 52.2 47.7 37.7 47.7 
Thrombocyte Counts 
Maximum (X 105/mm.3) 10.2 (-2) 12.1 (-3) 7.65 (4) 7.45 (9) 
Minimum 6.0 (28) 5.65 (28) 1.35 (28) 2.20 (23) 
Leukocyte Counts 
Maximum (/mm.3) 9,550 (0) 11,800 (-8) 9,650 (-5) 7,250 (-6) 
Minimum 4,800 (19) 5,000 (7) 1,350 (24) 300 (23) 
Serum Proteins 
Maximum (gm. %) 
Stable 
5.5 (-5) 
Stable 
7.0 (21) 
Decrease 
5.0 (-3) 
Decrease 
5.9 (-6) 
Minimum 4.8 (0) 5.2 (28) 4.1 (21) 4.2 (23) 
Diarrhea No No No No 
Death Killed (28) Killed (28) Killed (28) Died (28) 
Gross Lesions No No Yes® Yes® 
Lymphoid Depletion Yes Yes Yes Yes 
0Indicates day of occurrence of event. 
L^esions not thought to be due to the compound. 
56 
The leukocyte counts in the calves treated with UM appeared to 
show a graded degree of leukopenia corresponding with the increasing 
dosage levels. The leukocyte counts were lower with the two higher dosage 
levels of UN than with the comparable higher dosage levels of HN2, A 
relative lymphocytosis of over 85 percent was observed during the leuko­
penic stages in both animals receiving the two higher levels of UM. 
The two lower dosage levels of UM did not produce as low leukocyte counts 
as did the comparable two lower levels of HN2. While the responses of 
the leukocytes appeared to be graded,-it would be more appropriate to 
conclude that the responses of leukocytes are better qualitative criteria 
than quantitative. 
The serum proteins and the albumin-globulin ratios fluctuated apprec­
iably. The total proteins showed a decline but did not get below 4.0 
gm. per 100 ml. of serum. There were no definite trends observed in the 
albumin-globulin ratios. 
Diarrhea was not a problem in any calves treated with UM including 
the calf which received the highest dosage level. This finding was in 
contrast to the calf which received the highest level of HN2, 
Death occurred only in calf # 16 which received the highest dosage 
level of UM. The other three calves were electrocuted at the end of the 
experiment. The time of occurrence of death in the calf receiving the 
highest dosage level of UM was comparable to the time of death of the 
calf receiving the 2.288^ moles of HN2. This finding again suggests that 
UM is two times as toxic as HN2 to the calf. 
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Gross lesions were observed in the calves which received the two 
higher levels of UM. The calf which received 1.144jumoles per kg. per 
week had multifocal areas of pneumonia in all lobes of the lungs and 
petechial hemorrhages on the epicardium. The calf which received 0.572 
m^oles per kg. per week had pneumonia-like areas in a few lobes of the 
lungs and petechial hemorrhages on the serosal surfaces of the spleen 
and rumen. All of the lesions could be attributed to a "toxemia" due 
to a secondary bacterial infection and the UM did not appear to be the 
primary cause of the lesions. The lung lesions were confirmed as 
pneumonia by microscopic examination of the tissues. 
Lymphoid depletion in the thymus, spleen and lymph nodes was the 
main microscopic finding. There appeared to be a graded amount of 
lymphoid depletion corresponding with the graded dosage levels of UM. 
Detailed discussion and examination of these lymphoid tissues will be 
presented in a later section. 
The findings of this experiment with UM suggested quantitative 
responses as indicated by the degree of leukopenia and the graded occur­
rence of lymphoid depletion. These findings also appear to confirm 
previously reported results that on a molar basis UM is two times as toxic 
as HN2 to the calf. 
Quantitative Dose-Response Relationships 
The responses of the experimental calves which appeared to be quanti­
tatively related to the graded dosage levels of HN2 and UM were the time 
of occurrence of death and the appearance of graded amounts of lymphoid 
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depletion. The clinical and hematologic findings in calves which received 
HN2 or DM gave suggestions of quantitative responses, but did not appear 
suitable for use in a biological assay system. 
Time of death 
Single injection studies with HN2 at 4.576yimoles per kg. and UM at 
2.288 jumoles per kg. showed that the time of occurrence of death in 
calves was the same in both instances. Figure 3 illustrates these find­
ings. It is of interest to note that the dosage level of HN2 at 2.288 
yimoles per kg. did not produce death in a calf during the experimental 
period. There was no apparent difference in the time of deaths of 
calves given UM with the two different solvents. 
Figure 4 illustrates the times of occurrence of deaths of calves 
which received four treatments of HN2 or UM. Deaths occurred only with 
the dosage levels of 2.288yimoles of HN2 per kg. per week and 1.143 jimoles 
of UM per kg. per week. The times of occurrence of the deaths in both 
calves were 27-28 days. 
The times of occurrence of death in calves given single or multiple 
injections of HN2 or UM indicate that UM is twice as toxic as HN2 to the 
calf. These findings confirm previous reports with these compounds given 
to calves in graded daily dosage levels (1). The findings with the single 
dose, multiple weekly dose and daily dose regimens indicate that the time 
of occurrence of death in calves with HN2 and UM is quantitative and is 
a good assay criterion. 
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Lymphoid depletion 
The microscopic lesions in the thymus, lymph nodes and spleen of 
calves treated with HN2 or UN gave definite indications of a graded 
response. The changes in these tissues were lymphoid depletion with a 
reticulum-type cell infiltration. These changes varied from a decrease 
in lymphoid germinal centers to a loss of a clear cortico-medullary 
junction to an almost complete absence of any lymphoid tissue. 
Figure 5 shows a photomicrograph of the right popliteal lymph node 
from calf # 2 which received a single injection of 4.576^ moles of HN2 
per kg. and Figure 6 shows a photomicrograph of a similar lymph node 
taken from calf # 10 which received a single injection of 2.288yimoles of 
UM per kg. The sections show that lymphoid depletion of almost equal 
intensity occurred in both animals. The tissue changes in the lymph 
nodes consisted of almost complete loss of all germinal centers with 
reticulum-type cell infiltration. A similar lymph node from calf # 11 
(not shown) which also received 2.288 jimoles of UM had a similar amount 
of lymphoid damage. The lymph node from calf # 3 which received 2.288 
jjmoles of HN2 per kg. (not shown) did not show the marked lymphoid 
depletion of the other calves. 
The tissue changes observed in the spleens of the calves appeared to 
be much more severe than those observed in the lymph nodes. Figures 7 
and 8 show photomicrographs of spleen sections from calves # 2 and # 10. 
These sections show that the germinal centers are absent or inactive. 
These sections also show a marked loss of cellular structures which is 
not observed in the lymph node tissue sections. This marked loss of 
Figure 5. Right popliteal lymph node from calf # 2 which received 
a single injection of HN2 at 4.576/imoles per kg. 
Marked lymphoid depletion is present with no active 
germinal centers and loss of the cortlco-medullary 
junctions. The sinusoids are highly congested. ( X 50) 
Figure 6. Right popliteal lymph node from calf # 10 which 
received a single injection of UM in PSS at 2.288 
yimoles per kg. Marked lymphoid depletion is present 
with no active germinal centers. Lymphocytes are 
present but decreased in number. The sinusoids are 
highly congested. (X 50) 

Figure 7. Spleen from calf # 2. There is complete loss of 
splenic tissue which accentuates the trabecula. The 
tissue is congested. (X 50) 
Figure 8. Spleen from calf // 10. Marked lymphoid depletion is 
present with inactive germinal centers and a heavy 
infiltration of reticulum-type cells. The tissue 
is congested. (X 50) 
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cellular structures accentuates the splenic trabecular and leaves con­
gested sinusoids in a majority of each section. A similar amount of 
lymphoid depletion was observed in the spleen from calf # 11. The 
amount of lymphoid depletion in the spleen of calf # 3 was much less 
than in the other three animals. 
The results indicate that HN2 and UM readily acted upon the lymphoid 
tissues. It was thought that the greater amount of lymphoid depletion 
observed in the spleen could have been due to the greater blood supply 
of the spleen as compared to the popliteal lymph node and hence would 
allow more compound to bathe the splenic tissues. 
The appearance of almost equal amounts of lymphoid depletion in the 
respective tissues with these two compounds given in single injections 
at dosage levels differing by a factor of two, suggests that UM is approx­
imately two times more toxic than HN2 to the calf. These findings are 
also suggestive of a quantitative response in lymphoid tissues. The 
results also show that lymphoid tissue is very labile and can respond in 
a short period of time to rather high dosage.levels of these toxic agents. 
The multiple administration of graded dosage levels of HN2 and 
corresponding one half molar dosage levels of UM produced graded amounts 
of lymphoid depletion in calves. The magnitude of the lymphoid depletion 
observed in the calves with corresponding dosage levels of HN2 and UM 
appeared similar. 
Figures 9-14 show photomicrographs of histologic sections of the 
right popliteal lymph nodes of calves given the three higher graded dosage 
levels of HN2 or UM. The lymph node sections from the two calves which 
Figure 9. Right popliteal lymph node from calf # 4 which received 
0.572yimoles of HN2 per kg. for 4 treatments. The 
tissue has lymphoid depletion but germinal centers are 
present. A cortico-medullary junction is present. 
(X 50) 
Figure 10. Right popliteal lymph node from calf # 19 which 
received 0.286_/imoles of UM for 4 treatments. The 
tissue has large numbers of infiltrating reticulum-
type cells but a cortico-medullary junction is 
visible. (X 50) 

Figure 11. Right popliteal lymph node from calf // 7 which 
received 1.144^ moles of HN2 per kg. for 4 treatments. 
Marked lymphoid depletion with loss of the cortico-
medullary junction has occurred. Infiltration with 
reticulum-type cells has occurred. (X 50) 
Figure 12. Right popliteal lymph node from calf # 15 which 
received 0.572 jmoles of UM per kg. for 4 treatments. 
Small amounts of lymphoid tissue are near the sub­
capsular sinus and surrounding the trabecula but the 
majority of the section consists of reticulum-type 
cells. (X 50) 
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Figure 13. Right popliteal lymph node from calf # 8 which 
received 2.288^ moles of HN2 per kg. for 4 treatments. 
A dense area of lymphocytes is r.djacent to the sub­
capsular sinus which gives the appearance of a 
cortico-medullary junction. There is engorgement 
of the sinusoids. (X 50) 
Figure 14. Right popliteal lymph node from calf # 16 which 
received 1.144^ moles of UM per kg. for 4 treatments. 
The tissue shows few lymphocytes dispersed in sheets 
of reticulum-type cells. The sinusoids are dilated 
and some congestion is present. (X 50) 
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received the lowest dosage levels of HN2 and UM, calves # 5 and # 17 (not 
shown) had small amounts of lymphoid depletion. The lymph node sections 
from the calves given the higher dosage levels of HN2 and UM show grada­
tions of lymphoid depletion from a decrease in the number of germinal . . 
centers to a loss of the cortico-medullary junction to almost complete 
loss of the germinal centers. 
The lymphoid depletion observed in the splenic tissues was more 
severe than that observed in the lymph nodes and was also of a graded 
nature. Figures 15-20 show photomicrographs of spleens from the experi­
mental calves which received the three higher dosage levels of HN2 and 
UM. Calves # 5 and # 17 had very little tissue damage due to the lowest 
dosage levels of HN2 and UM. Here, as in the lymph nodes, there was a 
gradation of lymphoid depletion corresponding with the increasing dosage 
levels of IÎN2 and UM. The spleens from calves receiving the corresponding 
dosage levels of HN2 and UM appeared to show lymphoid depletion of an 
equal magnitude. 
The tissue changes observed in the lymphoid tissues of calves given 
graded dosage levels of HN2 and UM indicated that this tissue was capable 
of showing a graded response to these two compounds. Graded tissue 
changes are difficult to classify, but the presence of graded amounts of 
lymphoid depletion in response to graded dosage levels of these two 
alkylating agents indicated that it does occur and can be detected. 
The limited numbers of lymphoid tissues sectioned and examined in 
these studies indicated that more lymphoid tissues should be investigated. 
Figure 15. Spleen from calf # 4 which received 0.572jumoles of 
HN2 per kg. for 4 treatments. Some lymphoid depletion 
has occurred but several germinal centers are present. 
The parenchyma is composed of reticulum-type cells 
interspersed with lymphoid cells. The tissue is 
congested. (X 50) 
Figure 16. Spleen from calf # 19 which received 0.286yimoles of 
UM per kg. for 4 treatments. Few germinal centers 
are present. The majority of the section is com­
posed of reticulum-type cells with a few interspersed 
lymphocytes. The tissue is congested. (X 50) 

Figure 17. Spleen from calf # 7 which received 1.144 yimoles of 
HN2 per kg. for 4 treatments. Marked lymphoid 
depletion is present with inactive germinal centers 
surrounded by sheets of reticulum-type cells. The 
sinusoids are congested. (X 50) 
Figure 18. Spleen from calf # 15 which received 0.572 ^moles of 
UM per kg. for 4 treatments. There is marked lymphoid 
depletion and the inactive germinal centers are 
surrounded by sheets of reticulum-type cells. The 
sinusoids are congested. (X 50) 

Figure 19. Spleen from calf # 8 which received 2.288 jamoles of 
HN2 per kg. for 4 treatments. Almost complete 
lymphoid depletion with loss of germinal centers has 
occurred. Few reticulum-type cells are present. The 
section is congested and the trabecule are accentuated. 
(X 50) 
Figure 20. Spleen from calf // 15 which received 1.144^ moles of 
UM per kg. for 4 treatments. Almost complete lymphoid 
depletion has occurred and no germinal centers are 
present. There are a few reticulum-type cells and " 
lymphocytes interspersed among the engorged sinusoids. 
(X 50) 
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Examination of all of the regional lymph nodes and some of the thoracic 
and abdominal lymph nodes should give sufficient evidence to confirm 
these graded responses of calves to graded dosage levels of alkylating 
agents. 
81 
DISCUSSION 
The ubiquity of the toxic properties of cancer chemotherapeutic 
agents has established a requirement for a more sensitive toxicity assay 
for these compounds. The undesirable activities of anticancer compounds 
have created the problem of treading the thin line which exists between 
death of the patient due to the chemotherapy or death due to the neo­
plastic growth. 
A mora sensitive assay system for the toxic properties of cancer 
chemotherapeutic agents could make it possible to engineer away from 
these toxic properties by the use of different isomers or analogues of 
presently used anticancer compounds. Conceivably, exploitation of this 
approach could lead to the detection and subsequent elimination of the 
toxic structures with retention of the anticancer properties. The use of 
this approach in conjunction with the elaborate assay systems for 
detecting antitumor activity could help to formulate better and safer 
cancer chemotherapeutic compounds. 
The calf, for many years, has not been in the forefront as an 
experimental animal because of its size and the associated management 
problems. Recently, investigators in cardiovascular research have 
observed that the young calf, essentially a monogastric animal, is approx­
imately the size of an average human and have begun to utilize this animal 
in surgical research in the cardiovascular area. 
The calf assay system has been shown to be the most sensitive assay 
animal for the toxic properties of two alkylating agents, mechloreth-
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amine«HCl and uracil mustard. This fact suggests that it could possibly 
be a more desirable assay animal than some of the more commonly used 
assay animals such as the rat, the mouse, the dog and the monkey. 
The appearance and detection of graded amounts of lymphoid depletion 
in calves in response to graded dosage levels of the two alkylating 
agents in addition to the quantitative times of death of calves treated 
with these two agents, enhance the stature of the calf as a bioassay 
animal for these types of toxic compounds. Certainly, if the calf is a 
better assay animal for these toxic compounds, the management problems 
of the calf which are mysterious to many investigators, would become of 
little consequence to these uninitiated. 
It is possible that the calf would not be accepted as a biological 
assay animal for the toxic properties of cancer chemotherapeutic agents. 
However, the fact that in the calf there was an apparent occurrence of 
graded amounts of lymphoid depletion due to graded amounts of the alkyl­
ating agents should suggest to investigators that they might re-evaluate 
the rat or mouse assay systems and study the lymphoid tissues more closely. 
The graded responses of lymphoid tissues of calves suggest that an 
appropriate chemical assay method which resembles in principle the 
ovarian ascorbic acid depletion analytical procedure for lutenizing 
hormone could be developed for detecting the amounts of lymphoid tissue 
change. This chemical assay method might be developed in the highly 
sensitive calf and then could be incorporated into the rat or mouse assay 
systems for the advantages of greater numbers and economy. 
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It is readily apparent that further experimentation is necessary 
to delineate the modes of action of the toxic properties and the anti­
cancer activities of cancer chemotherapeutic compounds in addition to the 
actual etiology(s) of neoplastic growths. Until adequate prophylactic 
measures are established against cancer, the use of the highly sensitive 
calf assay system could aid in the development of cancer chemotherapeutic 
agents with greater degrees of efficacy. 
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SUMMARY 
1. An experimental study was designed to determine the nature of the 
responses of calves to graded dosage levels of the cancer chemotherapeutic 
agents, mechlorethamine.HCl and uracil mustard. Various clinical, 
hematologic and tissue responses were observed and measured in order to 
attempt to delineate the natures of these responses. Single injection 
and graded multiple dosage studies were undertaken for each compound. 
The dosage levels of uracil mustard corresponded to one half of the 
mechlorethamine.HCl dosage levels used, on a molar basis. 
2. The qualitative responses observed in calves due to the effects of 
mechlorethamine.HCl and uracil mustard were decreases in the rate of 
weight gain, varying degrees of leukopenia, death and lymphoid depletion 
in several lymphoid tissues. 
3. The quantitative responses observed in calves due to graded dosage 
levels of these alkylating agents were the length of the time intervals 
following the initiation of treatments until death and the graded 
increases of lymphoid depletion corresponding with the graded increasing 
dosage levels. 
4. The responses observed in calves due to each dosage level of mechlor­
ethamine.HCl were also observed with the corresponding one half molar 
dosage levels of uracil mustard indicating a factor of two difference in 
the toxicity of uracil mustard and mechlorethamine.HCl on a molar basis. 
These facts confirmed previously reported data. 
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5. Thrombocytopenia was observed only in the calves receiving the two 
highest dosage levels of uracil mustard in the multiple dosage studies. 
6. A modified technique for determining alkylating agents using gamma-
(4-nitroben2yl)pyridine was developed for use in bovine plasma. The 
technique was applicable only for mechlorethamine«HCl. 
7. Plasma levels of mechlorethamine.HCl were monitored in all calves 
which received treatments with this alkylating agent. No relationships 
were established between graded dosage levels of mechlorethamine»HCl 
administered to calves and the detected plasma levels of this compound. 
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